UniProt P15056
Serine/threonine-protein kinase B-raf (P15056)
Serine/threonine-protein kinase B-raf (UniProt P15056), EC 2.7.11.1: 173 experimental structures and 1 predicted model on GenesisL1, 40 ligands bound, 221 pockets. Binding sites, druggability and experiment against prediction…
- UniProt
- P15056
- Protein
- Serine/threonine-protein kinase B-raf
- EC
- 2.7.11.1
- Experimental structures
- 173
- Predicted models
- 1
- Ligands
- 40
- Pockets
- 221 · 28 records with a druggable one
Structures
174 records of P15056 in the MolNFT archive: 173 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1UWH | The complex of wild type B-RAF and BAY439006. | x-ray diffraction | A, B | — | — |
| 1UWH | The complex of wild type B-RAF and BAY439006. | x-ray diffraction | A, B | — | — |
| 1UWJ | The complex of mutant V599E B-RAF and BAY439006. | x-ray diffraction | A, B | — | — |
| 1UWJ | The complex of mutant V599E B-RAF and BAY439006. | x-ray diffraction | A, B | — | — |
| 2FB8 | Structure of the B-Raf kinase domain bound to SB-590885 | x-ray diffraction | A, B | — | — |
| 2FB8 | Structure of the B-RAF kinase domain bound to sb-590885 | x-ray diffraction | A, B | — | — |
| 2L05 | Solution NMR Structure of the Ras-binding domain of Serine/threonine-protein kinase B-raf from Homo… | solution nmr | A | — | — |
| 2L05 | Solution NMR structure of the RAS-binding domain of SERINE/THREONINE- protein kinase B-RAF from… | solution nmr | A | — | — |
| 3C4C | B-Raf Kinase in Complex with PLX4720 | x-ray diffraction | A, B | — | — |
| 3C4C | B-RAF kinase in complex with PLX4720 | x-ray diffraction | A, B | — | — |
| 3D4Q | Pyrazole-based inhibitors of B-Raf kinase | x-ray diffraction | A, B | — | — |
| 3D4Q | Pyrazole-based inhibitors of B-RAF kinase | x-ray diffraction | A, B | — | — |
| 3IDP | B-Raf V600E kinase domain in complex with an aminoisoquinoline inhibitor | x-ray diffraction | B, A | — | — |
| 3IDP | B-RAF V600E kinase domain in complex with an aminoisoquinoline inhibitor | x-ray diffraction | B, A | — | — |
| 3II5 | The Complex of wild-type B-RAF with Pyrazolo pyrimidine inhibitor | x-ray diffraction | A, B | — | — |
| 3II5 | The complex of wild-type B-RAF with pyrazolo pyrimidine inhibitor | x-ray diffraction | A, B | — | — |
| 3NY5 | Crystal structure of the RBD domain of serine/threonine-protein kinase B-raf from Homo sapiens.… | x-ray diffraction | A, B, C, D | — | — |
| 3NY5 | Crystal structure of the rbd domain of SERINE/THREONINE-protein kinase B-RAF from homo sapiens.… | x-ray diffraction | A, B, C, D | — | — |
| 3PPJ | Human B-Raf Kinase in Complex with a Furopyridine Inhibitor | x-ray diffraction | A, B | — | — |
| 3PPJ | Human B-RAF kinase in complex with a furopyridine inhibitor | x-ray diffraction | A, B | — | — |
| 3PPK | Human B-Raf Kinase in Complex with a Non-Oxime Furopyridine Inhibitor | x-ray diffraction | A, B | — | — |
| 3PPK | Human B-RAF kinase in complex with a non-oxime furopyridine inhibitor | x-ray diffraction | A, B | — | — |
| 3PRF | Crystal Structure of Human B-Raf Kinase Domain in Complex with a Non-Oxime Furopyridine Inhibitor | x-ray diffraction | A, B | — | — |
| 3PRF | Crystal structure of human B-RAF kinase domain in complex with a non- oxime furopyridine inhibitor | x-ray diffraction | A, B | — | — |
| 3PRI | Crystal Structure of Human B-Raf Kinase in Complex with a Non-Oxime Furopyridine Inhibitor | x-ray diffraction | A, B | — | — |
| 3PRI | Crystal structure of human B-RAF kinase in complex with a non-oxime furopyridine inhibitor | x-ray diffraction | A, B | — | — |
| 3PSB | Furo[2,3-c]pyridine-based Inda Oximes as Potent and Selective B-Raf Inhibitors | x-ray diffraction | A, B | — | — |
| 3PSB | FURO[2,3-C]PYRIDINE-based indanone oximes as potent and selective B- RAF inhibitors | x-ray diffraction | A, B | — | — |
| 3PSD | Non-oxime pyrazole based inhibitors of B-Raf kinase | x-ray diffraction | A, B | — | — |
| 3PSD | Non-oxime pyrazole based inhibitors of B-RAF kinase | x-ray diffraction | A, B | — | — |
| 3Q4C | Crystal Structure of Wild Type BRAF kinase domain in complex with organometallic inhibitor CNS292 | x-ray diffraction | A, B | — | — |
| 3Q4C | Crystal structure of wild type braf kinase domain in complex with organometallic inhibitor CNS292 | x-ray diffraction | A, B | — | — |
| 3Q96 | B-Raf kinase domain in complex with a tetrahydronaphthalene inhibitor | x-ray diffraction | A, B | — | — |
| 3Q96 | B-RAF kinase domain in complex with a tetrahydronaphthalene inhibitor | x-ray diffraction | A, B | — | — |
| 3SKC | Human B-Raf Kinase in Complex with an Amide Linked Pyrazolopyridine Inhibitor | x-ray diffraction | A, B | — | — |
| 3SKC | Human B-RAF kinase in complex with an amide linked pyrazolopyridine inhibitor | x-ray diffraction | A, B | — | — |
| 3TV4 | Human B-Raf Kinase Domain in Complex with an Bromopyridine Benzamide Inhibitor | x-ray diffraction | A, B | — | — |
| 3TV4 | Human B-RAF kinase domain in complex with an bromopyridine benzamide inhibitor | x-ray diffraction | A, B | — | — |
| 3TV6 | Human B-Raf Kinase Domain in Complex with a Methoxypyrazolopyridinyl Benzamide Inhibitor | x-ray diffraction | A, B | — | — |
| 3TV6 | Human B-RAF kinase domain in complex with a methoxypyrazolopyridinyl benzamide inhibitor | x-ray diffraction | A, B | — | — |
| 4DBN | Crystal Structure of the Kinase domain of Human B-raf with a [1,3]thiazolo[5,4-b]pyridine derivative | x-ray diffraction | A, B | — | — |
| 4DBN | Crystal structure of the kinase domain of human B-RAF with a [1, 3]THIAZOLO[5,4-B]PYRIDINE… | x-ray diffraction | A, B | — | — |
| 4E26 | BRAF in complex with an organic inhibitor 7898734 | x-ray diffraction | A, B | — | — |
| 4E26 | Braf in complex with an organic inhibitor 7898734 | x-ray diffraction | A, B | — | — |
| 4E4X | Crystal Structure of B-Raf Kinase Domain in Complex with a Dihydropyrido[2,3-d]pyrimidi -based… | x-ray diffraction | A, B | — | — |
| 4E4X | Crystal structure of B-RAF kinase domain in complex with a DIHYDROPYRIDO[2,3-D]PYRIMIDINONE-based… | x-ray diffraction | A, B | — | — |
| 4EHE | B-Raf Kinase Domain in Complex with an Aminothienopyrimidine-based Inhibitor | x-ray diffraction | A, B | — | — |
| 4EHE | B-RAF kinase domain in complex with an aminothienopyrimidine-based inhibitor | x-ray diffraction | A, B | — | — |
| 4EHG | B-Raf Kinase Domain in Complex with an Aminopyridimine-based Inhibitor | x-ray diffraction | A, B | — | — |
| 4EHG | B-RAF kinase domain in complex with an aminopyridimine-based inhibitor | x-ray diffraction | A, B | — | — |
| 4FC0 | Crystal Structure of Human Kinase Domain of B-raf with a DFG-out Inhibitor | x-ray diffraction | A, B | — | — |
| 4FC0 | Crystal structure of human kinase domain of B-RAF with a dfg-out inhibitor | x-ray diffraction | A, B | — | — |
| 4FK3 | B-Raf Kinase V600E Oncogenic Mutant in Complex with PLX3203 | x-ray diffraction | A, B | — | — |
| 4FK3 | B-RAF kinase V600E oncogenic mutant in complex with PLX3203 | x-ray diffraction | A, B | — | — |
| 4G9C | Human B-Raf Kinase Domain bound to a Type II Pyrazolopyridine Inhibitor | x-ray diffraction | A, B | — | — |
| 4G9C | Human B-RAF kinase domain bound to a type II pyrazolopyridine inhibitor | x-ray diffraction | A, B | — | — |
| 4G9R | B-Raf V600E Kinase Domain Bound to a Type II Dihydroquinazoline Inhibitor | x-ray diffraction | A, B | — | — |
| 4G9R | B-RAF V600E kinase domain bound to a type II dihydroquinazoline inhibitor | x-ray diffraction | A, B | — | — |
| 4H58 | BRAF in complex with compound 3 | x-ray diffraction | A, B, C | — | — |
| 4H58 | Braf in complex with compound 3 | x-ray diffraction | A, B, C | — | — |
114 records more on the page itself.
Ligands
- ANP · Phosphoaminophosphonic acid-adenylate ester · in 12 records
- MG · Magnesium ion · in 12 records
- ZN · Zinc ion · in 7 records
- CL · Chloride ion · in 5 records
- AGS · Phosphothiophosphoric acid-adenylate ester · in 4 records
- SO4 · Sulfate ion · in 4 records
- 0LI · 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl) phenyl}benzamide · in 2 records
- 215 · (1Z)-5-(2-{4-[2-(dimethylamino)ethoxy]phenyl}-5-pyridin-4-yl-1H-imidazol-4-yl)indan-1-one oxime · in 2 records
- 29L · 2-{4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridin-4-yl)-1H-pyrazol-1-yl}ethanol · in 2 records
- 5I4 · ~{N}-[3-[5-(2-azanylpyrimidin-4-yl)-2-[(3~{S})-morpholin-3-yl]-1,3-thiazol-4-yl]-2-fluoranyl-phenyl]-2,5-bis(fluoranyl)benzenesulfonamide · in 2 records
- 6FS · N-[2-methoxy-5-({[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine · in 2 records
- 6NC · 2,2'-oxybis(N-{[4-(3-{2,6-difluoro-3-[(propane-1-sulfonyl)amino]benzoyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl]methyl}acetamide) · in 2 records
- 8EN · ~{N}-[3-(2-acetamidoimidazo[1,2-a]pyridin-6-yl)-4-methyl-phenyl]-3-(trifluoromethyl)benzamide · in 2 records
- 92D · N-(3-tert-butylphenyl)-4-methyl-3-[6-(morpholin-4-yl) pyrimidin-4-yl]benzamide · in 2 records
- BEN · Benzamidine · in 2 records
- K81 · N-{3-[2-(2-hydroxyethoxy)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl}-2-(trifluoromethyl)pyridine-4-carboxamide · in 2 records
- NH4 · Ammonium ion · in 2 records
- P06 · Dabrafenib · in 2 records
- QH1 · N-(3-{5-[(1-acetylpiperidin-4-yl)(methyl)amino]-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl}-2,4-difluorophenyl)propane-1-sulfonamide · in 2 records
- 324 · N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide · in 1 record
- 4EF · 3-[(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-N-methyl-4-(morpholin-4-yl)benzenesulfonamide · in 1 record
- 4Z5 · 1-(3,3-dimethylbutyl)-3-{2-fluoro-4-methyl-5-[7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl]phenyl}urea · in 1 record
- 54J · N-(3-{5-[(1-ethylpiperidin-4-yl)(methyl)amino]-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl}-2,4-difluorophenyl)propane-1-sulfonamide · in 1 record
- 5XJ · 6-[2-[[3-(dimethylsulfamoylamino)-2,6-bis(fluoranyl)phenyl]amino]pyridin-3-yl]-7~{H}-purine · in 1 record
- 6DC · N-{2-cyano-3-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino]phenyl}propane-1-sulfonamide · in 1 record
- 6N9 · N-{2,4-difluoro-3-[5-(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]phenyl}propane-1-sulfonamide · in 1 record
- 92J · N-{2-methyl-5'-(morpholin-4-yl)-6'-[(oxan-4-yl)oxy][3, 3'-bipyridin]-5-yl}-3-(trifluoromethyl)benzamide · in 1 record
- A1AHE · N-[3-fluoro-4-({7-[(3-fluoropyridin-2-yl)oxy]-4-methyl-2-oxo-2H-1-benzopyran-3-yl}methyl)pyridin-2-yl]-N'-methylsulfuric diamide · in 1 record
- A1AN9 · N-{2-chloro-3-[(3,5-dimethyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino]-4-fluorophenyl}-3-fluoropropane-1-sulfonamide · in 1 record
- ACP · Phosphomethylphosphonic acid adenylate ester · in 1 record
Experiment against prediction
- 4XV1 chain A against the predicted model P15056: TM-score 0.98, RMSD 0.83 Å
- 4XV1 chain A against the predicted model P15056: TM-score 0.98, RMSD 0.83 Å
- 5ITA chain A against the predicted model P15056: TM-score 0.98, RMSD 0.83 Å
- 5ITA chain A against the predicted model P15056: TM-score 0.98, RMSD 0.83 Å
- 4XV3 chain A against the predicted model P15056: TM-score 0.98, RMSD 0.87 Å
- 4XV3 chain A against the predicted model P15056: TM-score 0.98, RMSD 0.87 Å
- 5FD2 chain A against the predicted model P15056: TM-score 0.98, RMSD 0.87 Å
- 5FD2 chain A against the predicted model P15056: TM-score 0.98, RMSD 0.87 Å
- 4FK3 chain A against the predicted model P15056: TM-score 0.98, RMSD 0.93 Å
- 4FK3 chain A against the predicted model P15056: TM-score 0.98, RMSD 0.93 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.